1.
|
PW InghamAP McMahonHedgehog signaling in
animal development: paradigms and principlesGenes
Dev1530593087200110.1101/gad.93860111731473
|
2.
|
M Pasca di MaglianoM HebrokHedgehog
signaling in cancer formation and maintenanceNat Rev
Cancer3903911200314737121
|
3.
|
H ZhuH-W LoThe human glioma-associated
oncogene homolog 1 (GLI1) family of transcription factors in gene
regulation and diseasesCurr
Genomics11238245201010.2174/13892021079123310821119888
|
4.
|
WJ IngramCA WickingSM GrimmondAR ForrestBJ
WainwrightNovel genes regulated by sonic hedgehog in pluripotent
mesenchymal
cellsOncogene2181968205200210.1038/sj.onc.120597512444557
|
5.
|
M Duman-ScheelL WengS XinW DuHedgehog
regulates cell growth and proliferation by inducing cyclin D and
cyclin ENature417299304200210.1038/417299a12015606
|
6.
|
DN WatkinsDM BermanSG BurkholderB WangPA
BeachySB BaylinHedgehog signaling within airway epithelial
progenitors and in small-cell lung
cancerNature422313317200310.1038/nature0149312629553
|
7.
|
M KuboM NakamuraA TasakiHedgehog signaling
pathway is a new therapeutic target for patients with breast
cancerCancer
Res6460716074200410.1158/0008-5472.CAN-04-041615342389
|
8.
|
SP ThayerMP di MaglianoPW HeiserHedgehog
is an early and late mediator of pancreatic cancer
tumorigenesisNature425851856200310.1038/nature0200914520413
|
9.
|
CM RudinCL HannJ LaterraTreatment of
medulloblastoma with hedgehog pathway inhibitor GDC-0449N Engl J
Med36111731178200910.1056/NEJMoa090290319726761
|
10.
|
I CaroJA LowThe role of the hedgehog
signaling pathway in the development of basal cell carcinoma and
opportunities for treatmentClin Cancer
Res1633353339201010.1158/1078-0432.CCR-09-257020439455
|
11.
|
DD Von HoffPM LoRussoCM RudinInhibition of
the hedgehog pathway in advanced basal-cell carcinomaN Engl J
Med36111641172200919726763
|
12.
|
JA LowFJ de SauvageClinical experience
with hedgehog pathway inhibitorsJ Clin
Oncol2853215326201010.1200/JCO.2010.27.994321041712
|
13.
|
JY YangAA MarghoobEmerging treatments and
signaling pathway inhibitorsSemin Cutan Med Surg31S14S182011
|
14.
|
JK ChenJ TaipaleMK CooperPA
BeachyInhibition of hedgehog signaling by direct binding of
cyclopamine to smoothenedGenes
Dev1627432748200210.1101/gad.102530212414725
|
15.
|
Z YuanJA GoetzS SinghFrequent requirement
of hedgehog signaling in non-small cell lung
carcinomaOncogene2610461055200710.1038/sj.onc.120986016909105
|
16.
|
Y MaS FieringC BlackTransgenic cyclin E
triggers dysplasia and multiple pulmonary adenocarcinomasProc Natl
Acad Sci USA10440894094200710.1073/pnas.060653710417360482
|
17.
|
GJP DijkgraafB AlickeL WeinmannSmall
molecule inhibition of GDC-0449 refractory smoothened mutants and
downstream mechanisms of drug resistanceCancer
Res71435444201110.1158/0008-5472.CAN-10-287621123452
|
18.
|
RL YauchGJP DijkgraafB AlickeSmoothened
mutation confers resistance to a hedgehog pathway inhibitor in
medulloblastomaScience326572574200910.1126/science.117938619726788
|
19.
|
F GalimbertiSL ThompsonX LiuTargeting the
cyclin E-cdk-2 complex represses lung cancer growth by triggering
anaphase catastropheClin Cancer
Res16109120201010.1158/1078-0432.CCR-09-215120028770
|
20.
|
X LiuLF SempereH OuyangMicroRNA-31
functions as an oncogenic microRNA in mouse and human lung cancer
cells by repressing specific tumor suppressorsJ Clin
Invest12012981309201010.1172/JCI3956620237410
|
21.
|
X LiuLF SempereF GalimbertiUncovering
growth-suppressive microRNAs in lung cancerClin Cancer
Res1511771183200910.1158/1078-0432.CCR-08-135519228723
|
22.
|
S GuptaN TakebeP LorussoTargeting the
hedgehog pathway in cancerTher Adv Med
Oncol2237250201010.1177/1758834010366430
|
23.
|
U McDermottSV SharmaL DowellIdentification
of genotype-correlated sensitivity to selective kinase inhibitors
by using high-throughput tumor cell line profilingProc Natl Acad
Sci USA1041993619941200710.1073/pnas.070749810418077425
|
24.
|
U McDermottSV SharmaJ
SettlemanHigh-throughput lung cancer cell line screening for
genotype-correlated sensitivity to an EGFR kinase inhibitorMethods
Enzymol438331341200810.1016/S0076-6879(07)38023-318413259
|
25.
|
R: Test for Association/Correlation
Between Paired Sampleshttp://stat.ethz.ch/R-manual/R-patched/library/stats/html/cor.test.html
|
26.
|
rproject.orghttp://www.rproject.org/
|
27.
|
GSK Cancer Cell Line Genomic Profiling
Datahttps://cabig.nci.nih.gov/caArray_GSKdata/
|
28.
|
S BamfordE DawsonS ForbesThe COSMIC
(catalogue of somatic mutations in cancer) database and websiteBr J
Cancer91355358200415188009
|
29.
|
E LindströmT ShimokawaR ToftgårdPG
ZaphiropoulosPTCH mutations: distribution and analysesHum
Mutat27215219200616419085
|
30.
|
SJ FreemantleE DmitrovskyCyclin E
transgenic mice: discovery tools for lung cancer biology, therapy,
and preventionCancer Prev
Res315131518201010.1158/1940-6207.CAPR-10-029721149327
|
31.
|
Q FengD SekulaY GuoUBE1L causes lung
cancer growth suppression by targeting cyclin D1Mol Cancer
Ther737803788200810.1158/1535-7163.MCT-08-075319074853
|
32.
|
E MassarelliM Varella-GarciaX TangKRAS
mutation is an important predictor of resistance to therapy with
epidermal growth factor receptor tyrosine kinase inhibitors in
non-small-cell lung cancerClin Cancer
Res1328902896200710.1158/1078-0432.CCR-06-304317504988
|
33.
|
KH DragnevT MaJ CyrusBexarotene plus
erlotinib suppress lung carcinogenesis independent of KRAS
mutations in two clinical trials and transgenic modelsCancer Prev
Res4818828201110.1158/1940-6207.CAPR-10-037621636548
|
34.
|
H LinardouIJ DahabrehD
KanaloupitiAssessment of somatic k-RAS mutations as a mechanism
associated with resistance to EGFR-targeted agents: a systematic
review and meta-analysis of studies in advanced non-small-cell lung
cancer and metastatic colorectal cancerLancet
Oncol9962972200810.1016/S1470-2045(08)70206-718804418
|
35.
|
W PaoTY WangGJ RielyKRAS mutations and
primary resistance of lung adenocarcinomas to gefitinib or
erlotinibPLoS
Med2e17e17200510.1371/journal.pmed.002001715696205
|
36.
|
S SinghZ WangD Liang FeiHedgehog-producing
cancer cells respond to and require autocrine hedgehog
activityCancer
Res7144544463201110.1158/0008-5472.CAN-10-231321565978
|
37.
|
J VestergaardMW PedersenN PedersenHedgehog
signaling in small-cell lung cancer: frequent in vivo but a rare
event in vitroLung
Cancer52281290200610.1016/j.lungcan.2005.12.01416616798
|
38.
|
JK ChenJ TaipaleKE YoungT MaitiPA
BeachySmall molecule modulation of smoothened activityProc Natl
Acad Sci USA991407114076200210.1073/pnas.18254289912391318
|
39.
|
F GalimbertiSL ThompsonS RaviDA ComptonE
DmitrovskyAnaphase catastrophe is a target for cancer therapyClin
Cancer Res1712181222201110.1158/1078-0432.CCR-10-117821288923
|
40.
|
J Sims-MourtadaJG IzzoJ AjaniKSC ChaoSonic
hedgehog promotes multiple drug resistance by regulation of drug
transportOncogene2656745679200710.1038/sj.onc.121035617353904
|
41.
|
T TangJY TangD LiTargeting superficial or
nodular basal cell carcinoma with topically formulated small
molecule inhibitor of smoothenedClin Cancer
Res1733783387201110.1158/1078-0432.CCR-10-337021558397
|